|Molecular Weight:||5136 g/mol|
Blank rubber stopper vials, without label as with all research peptides.
Tesamorelin, also known as TH9507, is a growth hormone-releasing hormone (GHRH) analog that has been shown to increase growth hormone and IGF-1 levels. Tesamorelin is currently the most effective GH releasing hormone on the market.. The peptide consists of all 44 amino acids from human growth hormone-releasing hormone and contains an extra hexenoic acid group, which limits its degradation.
Tesamorelin stimulates the release of growth hormone by activating the ghrelin receptor found in the brain. Activating this receptor and increasing the levels of growth hormone within the body can modulate food intake and energy metabolism and also influences glucose and fat metabolism. Tesamorelin will stimulate the secretion of the whole family of growth hormone peptides normally secreted by the pituitary gland. These hormones will stimulate increases in bone density and collagen production, as well as boosting the immune system. They will also stimulate the production of lean muscle mass. Growth hormone release will also accelerate fat loss and weight loss and stimulate anabolic effects via growth hormone induced fat breakdown . This is why the peptide is currently marketed as Egrifta, the FDA-approved drug for reducing excess abdominal fat in HIV-infected patients . In clinical trials the drug was shown to reduce visceral fat by around 18% and also reduced trunk fat, waist circumference and waist to hip ratio. In healthy males, tesamorelin was shown to enhance natural GH pulsatility and increased IGF-I without altering insulin sensitivity . The authors also suggest that tesamorelin may be useful at counteracting the reduction in GH secretion seen in overweight and obese patients. Additionally, human studies on a healthy and aging population showed that short-term treatment with tesamorelin improved the brain function for healthy and memory-impaired older individuals . The same study also demonstrated that the peptide had a positive effect on verbal memory in adults who were at high risk of developing Alzheimer’s disease.
The half-life of tesamorelin is estimated to be between 26 and 38 minutes, but its ability to stimulate growth hormone secretion has been clearly demonstrated after two weeks of once-daily dosing . For fat loss and muscle growth, tesamorelin should be administered by subcutaneous injection at a dose of 2 mg, following reconstitution in BAC water. For cognitive benefits the peptide can be administered at 1 mg per day. The treatment cycle should run for two weeks, followed by two weeks of withdrawal.
Tesamorelin administration has been shown to be well tolerated, with no serious adverse events observed . The peptide is registered as an FDA-approved drug and has therefore been subjected to extensive clinical testing in humans. However, some minor side effects reported following administration of the drug include nausea and muscle aches.
Not for human consumption, for research purposes only.
WARNINGS AND PRECAUTIONS (FDA Egrifta document)
• Increased risk of neoplasms: Preexisting malignancy should be inactive and its treatment complete prior to starting EGRIFTA SV. Discontinue EGRIFTA SV if there is any evidence of recurrent malignancy. (5.1)
• Elevated IGF-1: EGRIFTA SV stimulates GH production and increases serum IGF-1, a growth factor. The effects of prolonged elevations in IGF-1 levels are unknown Monitor IGF-1 levels during EGRIFTA SV therapy. Consider discontinuing in patients with persistent elevations. (5.2)
• Fluid retention: May occur with EGRIFTA SV and may include edema, arthralgia, and carpal tunnel syndrome. (5.3)
• Glucose intolerance or diabetes mellitus: May develop with EGRIFTA SV use. Evaluate glucose prior to and during therapy. (5.4)
• Hypersensitivity reactions: Have occurred in clinical trials. Advise patients to seek immediate medical attention and discontinue treatment if suspected. (5.5) • Increased mortality in patients with acute critical illness: Consider discontinuation in critically ill patients. (5.7)